Results 1 to 4 of 4

Thread: Phase 3 results for VX-659 triple combo

  1. #1
    Super Moderator
    Join Date
    Sep 2016
    Posts
    126

    Phase 3 results for VX-659 triple combo

    I'm guessing most have seen this already, but thought I'd share in case you missed it:

    Incredible Phase 3 results for VX-659!!!

    From Vertex Press Release on 11/27:

    Two Phase 3 Studies of the Triple Combination of VX-659, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis

    -Mean absolute improvement in ppFEV1 of 14.0 percentage points from baseline at week 4 in people with one F508del mutation and one minimal function mutation compared to placebo (p<0.0001)-

    -Mean absolute improvement in ppFEV1 of 10.0 percentage points from baseline at week 4 when VX-659 was added in people with two F508del mutations already receiving tezacaftor and ivacaftor compared to control group of placebo added to tezacaftor and ivacaftor (p<0.0001)-

    -Safety and efficacy profile supports potential submission of a New Drug Application for the VX-659 triple combination regimen-

    -Two Phase 3 studies of the triple combination of VX-445, tezacaftor and ivacaftor are now fully enrolled with data expected in the first quarter of 2019-

    https://investors.vrtx.com/news-rele...tezacaftor-and

  2. #2
    Junior Member
    Join Date
    Feb 2018
    Posts
    4
    Eagerly waiting for this or vx445 to come to market in 2019. It will be a game changer for many. 44 y/o male CFer. Heterogeneous.

  3. #3
    Senior Member
    Join Date
    Apr 2007
    Posts
    4,305
    So exciting!!!
    37 w/CF
    DDF508
    Mom to 2 boys

  4. #4
    Junior Member
    Join Date
    Feb 2015
    Posts
    28
    It will be life changing...I'm in this study. It's all good 👍🏼

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •